aldosterone has been researched along with Necrosis in 22 studies
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 7.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 6.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 5.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 5.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| " Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels." | 3.70 | Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. ( Adler, GK; Kifor, I; Ochoa-Maya, MR; Rennke, HG; Rocha, R; Stier, CT; Williams, GH, 2000) |
| "Fibrosis is a fundamental component of the adverse structural remodeling of myocardium present in the failing heart." | 2.47 | Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. ( Ahokas, RA; Bhattacharya, SK; Gandhi, MS; Gerling, IC; Kamalov, G; Shahbaz, AU; Sun, Y; Weber, KT, 2011) |
| "Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase." | 2.43 | Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006) |
| "Aldosterone has several deleterious properties." | 2.41 | Aldosterone: cardiovascular assault. ( Struthers, AD, 2002) |
| "Reactive fibrosis is associated with elevations in plasma aldosterone concentrations that are inappropriate relative to dietary sodium intake." | 2.38 | Factors associated with reactive and reparative fibrosis of the myocardium. ( Brilla, CG; Weber, KT, 1992) |
| "Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis." | 1.36 | Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats. ( Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 1.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (27.27) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, MU | 1 |
| Zhao, W | 3 |
| Zhao, T | 2 |
| Al Darazi, F | 1 |
| Ahokas, RA | 5 |
| Sun, Y | 5 |
| Bhattacharya, SK | 5 |
| Gerling, IC | 5 |
| Weber, KT | 8 |
| Gandhi, MS | 2 |
| Deshmukh, PA | 1 |
| Kamalov, G | 4 |
| Whaley, JT | 1 |
| Tichy, JR | 1 |
| Shahbaz, AU | 2 |
| Matsubara, BB | 2 |
| Franco, M | 1 |
| Janicki, JS | 2 |
| Matsubara, LS | 1 |
| Zia, AA | 1 |
| Newman, KP | 1 |
| McGee, JE | 1 |
| Ferron, L | 1 |
| Ruchon, Y | 1 |
| Renaud, JF | 1 |
| Capuano, V | 1 |
| Todkar, A | 1 |
| Di Chiara, M | 1 |
| Loffing-Cueni, D | 1 |
| Bettoni, C | 1 |
| Mohaupt, M | 1 |
| Loffing, J | 1 |
| Wagner, CA | 1 |
| Struthers, AD | 1 |
| Rocha, R | 2 |
| Martin-Berger, CL | 1 |
| Yang, P | 1 |
| Scherrer, R | 1 |
| Delyani, J | 1 |
| McMahon, E | 1 |
| WEXLER, BC | 1 |
| KITTINGER, GW | 1 |
| SELYE, H | 1 |
| Odedra, K | 1 |
| Ferro, A | 1 |
| Fazekas, AG | 1 |
| Kókai, K | 1 |
| Kovács, K | 1 |
| Robert, V | 1 |
| Silvestre, JS | 1 |
| Charlemagne, D | 1 |
| Sabri, A | 1 |
| Trouvé, P | 1 |
| Wassef, M | 1 |
| Swynghedauw, B | 1 |
| Delcayre, C | 1 |
| Campbell, SE | 1 |
| Stier, CT | 1 |
| Kifor, I | 1 |
| Ochoa-Maya, MR | 1 |
| Rennke, HG | 1 |
| Williams, GH | 1 |
| Adler, GK | 1 |
| Severson, JA | 1 |
| Fell, RD | 1 |
| Griffith, DR | 1 |
| Brilla, CG | 1 |
| Castleman, B | 1 |
| Scully, RE | 1 |
| McNeely, BU | 1 |
| Fisher, CE | 1 |
| Turner, FA | 1 |
| Horton, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720] | Phase 2 | 120 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for aldosterone and Necrosis
| Article | Year |
|---|---|
Cellular and molecular pathways to myocardial necrosis and replacement fibrosis.
Topics: Aldosterone; Animals; Disease Models, Animal; Fibrosis; Heart Failure; Humans; Hypercalciuria; Hyper | 2011 |
From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation.
Topics: Aldosterone; Animals; Calcium; Coronary Vessels; Disease Models, Animal; Hyperaldosteronism; Myocard | 2010 |
Aldosterone: cardiovascular assault.
Topics: Aldosterone; Autonomic Nervous System Diseases; Cardiomegaly; Endothelium, Vascular; Fibrinolysis; F | 2002 |
Neurohormones and heart failure: the importance of aldosterone.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Factors associated with reactive and reparative fibrosis of the myocardium.
Topics: Aldosterone; Animals; Cardiomyopathies; Fibroblasts; Fibrosis; Humans; Myocardium; Necrosis; Wound H | 1992 |
17 other studies available for aldosterone and Necrosis
| Article | Year |
|---|---|
Nebivolol: a multifaceted antioxidant and cardioprotectant in hypertensive heart disease.
Topics: Aldosterone; Animals; Antioxidants; Benzopyrans; Calcium; Cardiotonic Agents; Cytosol; Disease Model | 2013 |
Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism.
Topics: Acetazolamide; Aldosterone; Animals; Calcium; Chronic Disease; Disease Models, Animal; Homeostasis; | 2008 |
Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism.
Topics: Aldosterone; Animals; Calcium; Dinoprost; Disease Models, Animal; Glutathione Peroxidase; Homeostasi | 2010 |
Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats.
Topics: Aldosterone; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Felodipine; | 2010 |
T-type Ca²+ signalling regulates aldosterone-induced CREB activation and cell death through PP2A activation in neonatal cardiomyocytes.
Topics: Aldosterone; Animals; Animals, Newborn; Apoptosis; bcl-X Protein; Calcium Channels, T-Type; Calcium | 2011 |
Aldosterone deficiency adversely affects pregnancy outcome in mice.
Topics: Aldosterone; Animals; Blood Pressure; Cytochrome P-450 CYP11B2; Diet; Disease Models, Animal; Female | 2012 |
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Body Weight; Coronary Disease; Coronary Vessels | 2002 |
STEROIDS PRODUCED IN VITRO BY ADRENAL GLANDS OF NORMAL AND ARTERIOSCLEROTIC RATS DURING AND AFTER DRUG-INDUCED MYOCARDIAL NECROSIS.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aldosterone; Arteriosclerosis; Heart Failure; In Vitro Tech | 1965 |
Protection by a steroid-spirolactone against certain types of cardiac necroses.
Topics: Aldosterone; Heart; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Necrosis; Spironolac | 1960 |
From inflammation to fibrosis: a stiff stretch of highway.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Apoptosis; Cell Adhesion Molecules; Collagen | 2004 |
Effect of hexadimethrine bromide on the conversion of 4-14C-progesterone into aldosterone and corticosterone by rat adrenals.
Topics: Adrenal Glands; Aldosterone; Animals; Carbon Isotopes; Chromatography; Chromatography, Thin Layer; C | 1967 |
Biological determinants of aldosterone-induced cardiac fibrosis in rats.
Topics: Aldosterone; Animals; Blotting, Northern; Collagen; Fibrosis; Heart; Histocytochemistry; Hypertensio | 1995 |
Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride.
Topics: Aldosterone; Amiloride; Animals; Cardiomyopathies; Cicatrix; Collagen; Disease Models, Animal; Drug | 1993 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.
Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomyopathies; Enzyme Inhibi | 2000 |
Adrenocortical function in response to myocardial necrosis in exercise-trained rats.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Animals; Body Weight; Cardiomyopathies; Co | 1978 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1972.
Topics: Adenoma; Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Aldosterone; Diagnosis, Di | 1972 |
Remission of primary hyperaldosteronism after adrenal venography.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Aldosterone; Catheterization; Humans; Hyperaldosteronism; M | 1971 |